Stock listing
gettex:1S70 Cartesian Therapeutics, Inc. Aktie
German listing (gettex) of Cartesian Therapeutics, Inc. · home listing NASDAQ:RNAC
Follow Cartesian Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:RNAC
$6.14 USD -0.16 (-2.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RNAC
- Day range
- $5.89 – $6.32 USDNov 20, 2026
- Volume
- 279,308 sharesNov 20, 2026
- Market cap
- $187.3M USDAt the close on Nov 20, 2026 · price × 30.50M shares outstanding
- 52-week range
- $5.60 – $11.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.00M USDMedian day 117,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RNAC · Home | $6.14 USD | -0.16 (-2.5%) | 279,308 | $5.89 | $6.32 | $5.89 | $6.30 | Close on Nov 20, 2026 |
| Frankfurt:1S70 | €5.15 EUR | -0.50 (-8.8%) | — | €5.15 | €5.15 | €5.15 | €5.65 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RNAC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.14 | -0.16 | -2.5% | $5.89 | $6.32 | $5.89 | 279,308 | |
| $6.30 | +0.18 | +2.9% | $6.04 | $6.37 | $6.01 | 170,208 | |
| $6.12 | +0.04 | +0.7% | $6.12 | $6.24 | $5.89 | 232,800 | |
| $6.08 | -0.27 | -4.3% | $6.33 | $6.435 | $6.06 | 97,893 | |
| $6.35 | -0.005 | -0.1% | $6.39 | $6.40 | $6.16 | 106,818 | |
| $6.355 | -0.525 | -7.6% | $6.82 | $6.82 | $6.12 | 264,906 | |
| $6.88 | -0.01 | -0.1% | $6.95 | $7.09 | $6.70 | 134,041 | |
| $6.89 | -0.13 | -1.9% | $6.99 | $7.28 | $6.76 | 93,438 | |
| $7.02 | -0.51 | -6.8% | $7.66 | $7.905 | $6.87 | 313,315 | |
| $7.53 | +0.75 | +11.1% | $6.82 | $7.67 | $6.73 | 121,514 | |
| $6.78 | -0.04 | -0.6% | $6.85 | $6.91 | $6.46 | 184,785 | |
| $6.82 | +0.41 | +6.4% | $6.64 | $7.158 | $6.542 | 80,642 | |
| $6.41 | +0.07 | +1.1% | $6.37 | $6.68 | $6.37 | 97,714 | |
| $6.34 | -0.15 | -2.3% | $6.49 | $6.68 | $6.20 | 114,729 | |
| $6.49 | -0.26 | -3.9% | $6.72 | $6.755 | $6.44 | 78,798 | |
| $6.75 | +0.06 | +0.9% | $6.76 | $6.97 | $6.63 | 112,263 | |
| $6.69 | +0.23 | +3.6% | $6.43 | $6.73 | $6.29 | 113,922 | |
| $6.46 | +0.18 | +2.9% | $6.26 | $6.55 | $6.13 | 118,818 | |
| $6.28 | +0.10 | +1.6% | $6.21 | $6.31 | $6.07 | 105,631 | |
| $6.18 | -0.23 | -3.6% | $6.38 | $6.52 | $6.11 | 85,800 | |
| $6.41 | -0.01 | -0.2% | $6.33 | $6.642 | $6.24 | 89,200 | |
| $6.42 | +0.025 | +0.4% | $6.42 | $6.706 | $6.40 | 106,000 | |
| $6.395 | +0.315 | +5.2% | $6.09 | $6.525 | $6.071 | 168,600 | |
| $6.08 | -0.19 | -3.0% | $6.28 | $6.55 | $6.01 | 201,500 | |
| $6.27 | -0.31 | -4.7% | $6.62 | $6.65 | $6.25 | 112,700 | |
| $6.58 | +0.24 | +3.8% | $6.39 | $6.776 | $6.39 | 86,800 | |
| $6.34 | -0.23 | -3.5% | $6.55 | $6.69 | $6.33 | 173,400 | |
| $6.57 | -0.42 | -6.0% | $6.98 | $7.02 | $6.565 | 218,600 | |
| $6.99 | -0.065 | -0.9% | $7.03 | $7.147 | $6.95 | 107,800 | |
| $7.055 | +0.235 | +3.4% | $6.87 | $7.165 | $6.851 | 114,500 | |
| $6.82 | +0.14 | +2.1% | $6.68 | $6.82 | $6.50 | 214,400 | |
| $6.68 | -0.07 | -1.0% | $6.70 | $6.84 | $6.60 | 86,400 | |
| $6.75 | -0.39 | -5.5% | $7.15 | $7.23 | $6.75 | 171,200 | |
| $7.14 | -0.22 | -3.0% | $7.36 | $7.425 | $7.11 | 226,200 | |
| $7.36 | +0.14 | +1.9% | $7.32 | $8.05 | $7.29 | 200,400 | |
| $7.22 | +0.01 | +0.1% | $7.16 | $7.44 | $7.15 | 175,700 | |
| $7.21 | -0.03 | -0.4% | $7.31 | $7.57 | $7.15 | 166,900 | |
| $7.24 | +0.03 | +0.4% | $7.28 | $7.56 | $7.10 | 157,800 | |
| $7.21 | -0.20 | -2.7% | $7.32 | $7.345 | $7.01 | 109,100 | |
| $7.41 | -0.21 | -2.8% | $7.60 | $7.60 | $7.31 | 158,600 | |
| $7.62 | -0.25 | -3.2% | $7.86 | $7.87 | $7.415 | 205,800 | |
| $7.87 | -0.21 | -2.6% | $8.05 | $8.155 | $7.65 | 117,000 | |
| $8.08 | +0.14 | +1.8% | $8.03 | $8.32 | $7.95 | 161,700 | |
| $7.94 | -0.09 | -1.1% | $8.11 | $8.23 | $7.753 | 61,400 | |
| $8.03 | +0.17 | +2.2% | $7.88 | $8.26 | $7.66 | 211,400 | |
| $7.86 | -0.05 | -0.6% | $8.11 | $8.27 | $7.79 | 164,400 | |
| $7.91 | +0.02 | +0.3% | $7.95 | $8.03 | $7.72 | 118,000 | |
| $7.89 | -0.15 | -1.9% | $8.00 | $8.01 | $7.67 | 113,300 | |
| $8.04 | -0.15 | -1.8% | $8.19 | $8.262 | $7.955 | 110,200 | |
| $8.19 | -0.24 | -2.8% | $8.59 | $8.88 | $8.18 | 123,100 | |
| $8.43 | -0.26 | -3.0% | $8.53 | $8.53 | $8.25 | 128,300 | |
| $8.69 | -0.26 | -2.9% | $8.94 | $9.151 | $8.56 | 94,200 | |
| $8.95 | -0.32 | -3.5% | $9.11 | $9.26 | $8.75 | 61,400 | |
| $9.27 | +0.15 | +1.6% | $9.12 | $9.31 | $8.89 | 68,400 | |
| $9.12 | +0.04 | +0.4% | $9.19 | $9.50 | $8.80 | 134,900 | |
| $9.08 | -0.22 | -2.4% | $9.30 | $9.64 | $8.81 | 128,500 | |
| $9.30 | +0.02 | +0.2% | $9.16 | $9.479 | $8.86 | 112,100 | |
| $9.28 | -0.32 | -3.3% | $9.54 | $9.54 | $9.14 | 90,800 | |
| $9.60 | -0.37 | -3.7% | $9.93 | $10.61 | $9.55 | 65,600 | |
| $9.97 | -0.22 | -2.2% | $10.12 | $10.23 | $9.80 | 61,800 | |
| $10.19 | -0.19 | -1.8% | $10.30 | $10.36 | $10.06 | 65,800 | |
| $10.38 | +0.32 | +3.2% | $10.19 | $10.88 | $10.05 | 97,568 | |
| $10.06 | +0.02 | +0.2% | $10.05 | $10.29 | $9.50 | 104,239 | |
| $10.04 | -0.19 | -1.9% | $10.35 | $10.69 | $10.00 | 163,900 | |
| $10.23 | -0.26 | -2.5% | $10.34 | $10.43 | $9.86 | 134,700 |
Splits
1 split · NASDAQ:RNAC · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation |
- Ticker
- gettex:1S70
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 5, 2026
Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · Sep 29, 2026
2026 MGFA Scientific Session at AANEM
Conference · 14 slides
Latest news
Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 5, 2026
Closed $6.78 (-0.6%) on Nov 5, 2026
Cartesian Therapeutics Announces New Employment Inducement Grant
Nov 3, 2026
Closed $6.41 (+1.1%) on Nov 3, 2026
Cartesian Therapeutics Announces New Employment Inducement Grants
Oct 2, 2026
Closed $7.36 (+1.9%) on Oct 2, 2026
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Sep 29, 2026
Closed $7.24 (+0.4%) on Sep 29, 2026
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 6, 2026
Closed $8.76 (+4.9%) on Aug 6, 2026
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
Jun 9, 2026
Closed $6.85 (+16.9%) on Jun 9, 2026
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
May 26, 2026
Closed $6.45 (-4.4%) on May 26, 2026
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 12, 2026
Closed $8.70 (+2.0%) on May 12, 2026
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Apr 30, 2026
Closed $6.22 (-3.9%) on Apr 30, 2026
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
Mar 9, 2026
Closed $9.02 (+31.7%) on Mar 9, 2026
Cartesian Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 46 in all · newest Nov 5, 2026 · oldest 2020
- Calls
- 9 calls with a replay · 9 with a transcript · latest Aug 17, 2023
- Decks
- 52 decks · latest Sep 29, 2026
Where Cartesian Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RNAC · Home listing | NASDAQ | United States | USD |
| LS Exchange:A407YS | LS Exchange | Germany | EUR |
| Lang & Schwarz:A407YS | Lang & Schwarz | Germany | EUR |
| BOATS:RNAC | BOATS | United States | USD |
| gettex:1S70 · This page | gettex | Germany | EUR |
| Frankfurt:1S70 | Frankfurt | Germany | EUR |
| Munich:1S70 | Munich | Germany | EUR |
| Stuttgart:1S70 | Stuttgart | Germany | EUR |
Valuation
EV/sales 112× against a median of 14.4×: the highest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $114.5M USD
- P/E
- Loss
- EV/sales
- 112×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.23
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cartesian Therapeutics, Inc. · NASDAQ:RNAC | US$187.3M | US$114.5M | n/a | 112× | n/a | n/a | n/a | n/a | 1.23 |
| AC Immune SA · NASDAQ:ACIU | US$193.9M | US$110.5M | n/a | 4.7× | n/a | 6.0× | −181.9% | 0.1× | 1.56 |
| AN2 Therapeutics, Inc. · NASDAQ:ANTX | US$192.8M | US$128.4M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.54 |
| SillaJen, Inc. · KRX:215600 | US$192.3M | US$140.8M | n/a | 17.6× | n/a | 2.6× | −223.8% | 0.0× | n/a |
| Artiva Biotherapeutics, Inc. · NASDAQ:ARTV | US$186.9M | −US$123.1M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.34 |
| Inhibikase Therapeutics, Inc. · NASDAQ:IKT | US$185.2M | −US$8.17M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 1.50 |
| Inventage Lab, Inc. · KRX:389470 | US$184.8M | US$112.6M | n/a | 61.3× | n/a | 2.8× | −127.0% | 0.2× | n/a |
| Antengene Corporation Limited · HKEX:6996 | US$183.1M | US$107.0M | n/a | 6.8× | n/a | 1.3× | −227.0% | 0.3× | n/a |
| Whitehawk Therapeutics, Inc. · NASDAQ:WHWK | US$181.2M | US$11.70M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.35 |
| Sol-Gel Technologies Ltd. · NASDAQ:SLGL | US$180.6M | US$137.0M | n/a | 95.4× | n/a | 4.2× | n/a | 0.0× | 0.67 |
| Tanvex BioPharma, Inc. · TWSE:6541 | US$180.5M | US$225.7M | n/a | 11.3× | n/a | 1.2× | −222.8% | 0.4× | n/a |
| Median of the others | US$185.0M | US$111.5M | 14.4× | 1.9× | −222.8% | 0.0× | 1.35 |
Forecasts
6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 33.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.23 · 1 analyst
- Revenue, year to Dec 2026
- 383.4K · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Carsten Brunn | President, Chief Executive Officer, and Chairman, Board of Directors |
| Blaine Davis | Chief Financial Officer |
| Matthew Bartholomae | General Counsel, Secretary |
| Emily English | Chief Operations Officer |
| Peter Traber | Head of Research and Development |
Board
| Director | Role |
|---|---|
| Carsten Brunn | President, Chief Executive Officer, and Chairman, Board of Directors |
| Adrian Bot | |
| Kemal Malik | |
| Michael Singer | |
| Nishan de Silva | |
| Patrick Zenner | |
| Timothy Barabe | |
| Timothy Springer |
Events
Calls
| Call | When | Status |
|---|---|---|
| Selecta Biosciences, Inc. (SELB) Q2 2023 Earnings Call | Thu, Aug 17, 2023 · 8:30 AM ET | Replay |
| Selecta Biosciences, Inc. (SELB) Q1 2023 Earnings Call | Thu, May 04, 2023 · 8:30 AM ET | Replay |
| Selecta Biosciences, Inc. (SELB) Q3 2022 Earnings Call | Thu, Nov 03, 2022 · 8:30 AM ET | Replay |
| Selecta Biosciences, Inc. (SELB) Q2 2022 Earnings Call | Thu, Aug 04, 2022 · 8:30 AM ET | Replay |
| Selecta Biosciences, Inc. (SELB) Q1 2022 Earnings Call | Thu, May 05, 2022 · 8:30 AM ET | Replay |
| Selecta Biosciences, Inc. (SELB) Q3 2021 Earnings Call | Tue, Nov 09, 2021 · 8:30 AM ET | Replay |
| Selecta Biosciences, Inc. (SELB) Q2 2021 Earnings Call | Thu, Aug 12, 2021 · 8:30 AM ET | Replay |
| Selecta Biosciences, Inc. (SELB) Q1 2021 Earnings Call | Thu, May 13, 2021 · 8:30 AM ET | Replay |
| Selecta Biosciences, Inc. (SELB) Q4 2021 Earnings Call | Wed, Mar 10, 2021 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −0.6% |
| Q2 2026 | Aug 6, 2026 · Before open | +4.9% |
| Q1 2026 | Apr 30, 2026 · Before open | −3.9% |
| Q4 2025 | Mar 9, 2026 | +24.8% |
| Q3 2025 | Nov 6, 2025 · Before open | −1.6% |
| Q2 2025 | Aug 7, 2025 · Before open | −6.6% |
| Q1 2025 | May 8, 2025 · Before open | +2.7% |
| Q4 2024 | Mar 5, 2025 · Before open | +0.5% |
| Q3 2024 | Nov 7, 2024 · Before open | −0.4% |
| Q2 2024 | Aug 8, 2024 · Before open | −9.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · Before open | +0.2% |
| Q4 2023 | Mar 7, 2024 · Before open | −8.0% |
| Q3 2023 | Nov 13, 2023 · After close | +21.4% |
| Q2 2023 | Aug 17, 2023 · Before open | +2.8% |
| Q1 2023 | May 4, 2023 · Before open | −7.0% |
| Q4 2022 | Mar 2, 2023 · Before open | −1.3% |
| Q3 2022 | Nov 3, 2022 · Before open | +3.7% |
| Q2 2022 | Aug 4, 2022 · Before open | +13.9% |
| Q1 2022 | May 5, 2022 · Before open | +1.1% |
| Q4 2021 | Mar 10, 2022 · Before open | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 2026 MGFA Scientific Session at AANEM | Conference | 14 slides | Sep 29, 2026 |
| Investor Presentation (September 2026) | Investor deck | 33 slides | September 2026 |
| Investor Presentation (May 2026) | Investor deck | 31 slides | May 26, 2026 |
| Investor Presentation (January 2026) | Investor deck | 35 slides | Jan 9, 2026 |
| Investor Presentation (November 2025) | Investor deck | 30 slides | Nov 13, 2025 |
| American Academy of Neurology 2025 Annual Meeting | Conference | 14 slides | Apr 9, 2025 |
| Investor Presentation (April 2025) | Investor deck | 32 slides | Apr 8, 2025 |
| Investor Presentation (March 2025) | Investor deck | 19 slides | Mar 3, 2025 |
| Investor Presentation (January 2025) | Investor deck | 30 slides | Jan 13, 2025 |
| Corporate Update (December 2024) | Corporate update | 18 slides | Dec 3, 2024 |
Show 50 decks
This page holds 50 of 52 decks. Open Decks
IPO
Went public as SELECTA BIOSCIENCES INC. Priced at US$14.00 a share. Final prospectus filed on Jun 23, 2016.
- Price
- US$14.00 a share
- Shares offered
- 5,000,000 shares of common stock
- Offering size
- US$70 million
- Listing
- SELB on the Nasdaq Global Market
- Underwriters
- UBS Investment Bank, Stifel, Canaccord Genuity, Needham & Company · In the order on the cover
- Shares delivered
- On or about Jun 27, 2016
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 24, 2015 |
| Filed publicly | May 24, 2016 |
| Amended twice | Newest Jun 20, 2016 |
| Shares registered with an exchange | Jun 8, 2016 |
| Declared effective by the SEC | Jun 21, 2016 |
| Final prospectus, with the price | Jun 23, 2016 |
Filings
| Filing | Filed |
|---|---|
| CERTNAS · Nasdaq's certificate of listing | Jun 28, 2016 |
| 424B4 · Prospectus | Jun 23, 2016 |
| EFFECT · Notice that a registration is effective | Jun 21, 2016 |
| S-1MEF · Registration of more shares for the same offering | Jun 21, 2016 |
| FWP · Free writing prospectus | Jun 20, 2016 |
| S-1/A · Registration statement, amended | Jun 20, 2016 |
| CORRESP · Letter to the SEC | Jun 17, 2016 |
| CORRESP · Letter to the SEC | Jun 17, 2016 |
| CORRESP · Letter to the SEC | Jun 10, 2016 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 8, 2016 |
All 25 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jun 8, 2016 |
| UPLOAD · Letter from the SEC | Jun 8, 2016 |
| CORRESP · Letter to the SEC | Jun 6, 2016 |
| CORRESP · Letter to the SEC | Jun 6, 2016 |
| CORRESP · Letter to the SEC | Jun 3, 2016 |
| UPLOAD · Letter from the SEC | Jun 3, 2016 |
| CORRESP · Letter to the SEC | May 31, 2016 |
| S-1 · Registration statement | May 24, 2016 |
| DRS/A · Draft registration statement, amended | Apr 27, 2016 |
| DRS/A · Draft registration statement, amended | Mar 30, 2016 |
| DRS/A · Draft registration statement, amended | Mar 18, 2016 |
| DRSLTR · Letter to the SEC with a draft | Dec 29, 2015 |
| DRS/A · Draft registration statement, amended | Dec 29, 2015 |
| UPLOAD · Letter from the SEC | Dec 18, 2015 |
| DRS · Draft registration statement | Nov 24, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 23, 2016
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.80M | 38.9M | 26.0M | 110.8M | 85.1M | 16.6M | 6.68M | 903.0K | 207.0K | 8.08M |
| Cost of revenue | 1.55M | 2.04M | 42.7M | 47.7M | 45.2M | 15.3M | ||||
| Gross profit | 2.80M | 38.9M | 26.0M | 108.7M | 85.1M | 16.6M | 6.68M | 903.0K | 207.0K | 8.08M |
| Research and development | 58.0M | 45.1M | 71.3M | 72.4M | 68.7M | 54.5M | 42.7M | 47.7M | 45.2M | 29.7M |
| Selling, general and administrative | 31.5M | 30.1M | 40.5M | 23.9M | 20.9M | 18.9M | 16.4M | 18.2M | 18.8M | 13.1M |
| Operating income | -143.4M | -43.9M | -86.4M | 14.5M | -4.60M | -56.8M | -52.5M | -65.0M | -63.8M | -34.7M |
| Depreciation and amortization | 2.40M | 1.20M | 700.0K | 700.0K | 600.0K | 600.0K | 700.0K | 1.00M | 750.0K | 802.0K |
| EBITDA | -141.0M | -42.7M | -85.7M | 15.2M | -4.00M | -56.2M | -51.8M | -64.0M | -63.0M | -33.9M |
| Interest expense | 0 | 2.83M | 3.03M | 2.84M | 1.56M | 1.52M | 1.49M | 1.21M | 1.25M | |
| Income before tax | -139.5M | -77.1M | -238.7M | 34.8M | -9.72M | -68.9M | -55.4M | -65.3M | -65.3M | -36.2M |
| Income tax | -9.19M | 287.0K | -19.0M | -609.0K | 16.0M | 0 | 0 | 1 | 304.0K | 455.0K |
| Net income | -130.3M | -77.4M | -219.7M | 35.4M | -25.7M | -68.9M | -55.4M | -65.3M | -65.3M | -36.2M |
| Earnings per share, basic | -5.02 | -4.48 | -49.76 | 0.24 | -0.22 | -0.68 | -1.22 | -2.92 | -3.20 | -3.89 |
| Earnings per share, diluted | -5.02 | -4.49 | -49.76 | 0.10 | -0.22 | -0.68 | -1.22 | -2.92 | -3.20 | -3.89 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 125.1M | 212.6M | 76.9M | 106.4M | 114.1M | 138.7M | 89.9M | 37.4M | 70.6M | 58.7M |
| Short-term investments | 0 | 28.2M | 14.0M | 0 | 0 | 25.9M | 25.5M | |||
| Receivables | 1.11M | 872.0K | 5.87M | 6.60M | 9.91M | 7.22M | 5.00M | 0 | 63.0K | 215.0K |
| Inventory | 1.00M | -2.04M | 0 | |||||||
| Current assets | 129.3M | 216.6M | 90.7M | 148.1M | 144.4M | 151.3M | 96.7M | 42.1M | 98.7M | 86.8M |
| Property, plant and equipment | 12.2M | 9.91M | 2.11M | 2.79M | 2.14M | 1.40M | 1.22M | 2.13M | 2.09M | 2.05M |
| Goodwill | 48.2M | 48.2M | 48.2M | 0 | 0 | 0 | ||||
| Total assets | 296.4M | 435.0M | 305.1M | 165.9M | 159.9M | 165.4M | 99.6M | 44.5M | 101.1M | 89.3M |
| Accounts payable | 1.29M | 288.0K | 3.15M | 316.0K | 224.0K | 443.0K | 500.0K | 1.10M | 1.61M | 3.88M |
| Current liabilities | 14.9M | 23.0M | 68.2M | 25.1M | 72.3M | 81.5M | 34.9M | 35.1M | 11.0M | 13.7M |
| Long-term debt | 0 | 17.8M | 19.7M | 24.8M | 0 | 21.0M | 7.98M | |||
| Total debt | 0 | 14.0M | 11.0M | 37.9M | 35.3M | 35.3M | 19.3M | 21.4M | 21.0M | 12.0M |
| Total liabilities | 422.7M | 441.8M | 444.7M | 72.1M | 137.4M | 183.4M | 91.2M | 49.9M | 49.3M | 34.3M |
| Shareholders' equity | -126.2M | -6.80M | -440.2M | 93.8M | 22.5M | -18.0M | 8.40M | -5.42M | 51.8M | 55.0M |
| Shares outstanding | 26.0M | 25.8M | 5.40M | 153.0M | 123.6M | 108.1M | 86.3M | 22.5M | 22.3M | 18.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -73.9M | -23.7M | -51.2M | -31.6M | -60.4M | 34.9M | -51.4M | -59.2M | -52.0M | -19.8M |
| Capital spending | -5.45M | -9.09M | -206.0K | -1.20M | -1.08M | -815.0K | -47.0K | -884.0K | -733.0K | -586.0K |
| Free cash flow | -79.4M | -32.8M | -51.4M | -32.8M | -61.5M | 34.1M | -51.5M | -60.0M | -52.8M | -20.3M |
| Cash from investing | -5.45M | -8.74M | 34.6M | -15.0M | -17.1M | -741.0K | 229.0K | 25.3M | -2.10M | -22.1M |
| Cash from financing | -8.05M | 168.4M | -13.1M | 39.2M | 52.9M | 14.4M | 105.0M | 697.0K | 66.0M | 67.7M |
| Dividends paid | -184.0K | -28.0K | -25.5M | -4.57M | ||||||
| Share buybacks | 0 | -6.17M | 189.0K | 161.0K | 184.0K | 28.0K | 196.0K | 180.0K | 71.8M | |
| Change in cash | -87.4M | 136.0M | -29.8M | -7.40M | -24.6M | 48.5M | 53.9M | -33.3M | 12.0M | 26.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 22, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | Jun 9, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jun 9, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jun 2, 2026 | Other filings | SEC |
| 8-K · Current report | May 26, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Apr 30, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Apr 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2026 | Results | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 30, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 13, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 9, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jan 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 9, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 18, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 13, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 30, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 28, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 21, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 8, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 8-K · Current report | Jun 16, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 30, 2025 | Current report | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 8-K · Current report | Apr 29, 2025 | Management or board change | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 25, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 8-K · Current report | Mar 3, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 27, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jan 14, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jan 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| POS AM · Amendment to an effective registration | Jan 10, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Jan 10, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 10, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jan 10, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jan 10, 2025 | Other filings | SEC |
| 424B7 · Prospectus | Jan 8, 2025 | Offer document | SEC |
| 424B7 · Prospectus | Jan 8, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 8, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Jan 6, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 6, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 23, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Dec 19, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 19, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 19, 2024 | Other filings | SEC |
| S-3 · Registration statement | Dec 13, 2024 | Offer document | SEC |
| S-3 · Registration statement | Dec 13, 2024 | Offer document | SEC |
| S-3 · Registration statement | Dec 13, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 10, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 9, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 3, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 21, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 18, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 14, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 14, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 14, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Nov 7, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 15, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 4, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Oct 2, 2024 | Other filings | SEC |
| 424B7 · Prospectus | Oct 1, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 27, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 27, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 26, 2024 | Current report | SEC |
| 8-K · Current report | Sep 23, 2024 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | Sep 20, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 20, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 16, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 9, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 9, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 29, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | Aug 16, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Aug 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| PRE 14A · Preliminary proxy statement | Aug 2, 2024 | Meeting notice | SEC |
| S-1 · Registration statement | Aug 2, 2024 | Offer document | SEC |
| D | Jul 17, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 12, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 5, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2024 | Material contract | SEC |
| 8-K · Current report | Jun 17, 2024 | Management or board change | SEC |
| 8-K · Current report | May 22, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | May 10, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 22, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Apr 19, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
This page holds 200 of 877 filings. Open Filings
Cap table
Built by 6ix from Cartesian Therapeutics, Inc.’s releases · as of Oct 31, 2026
- Common shares
- 30,503,005
- Fully diluted
- 30,503,005
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 30,503,005 | Oct 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 31, 2026 | 30,503,005 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Samuel D Isaly Other companies: Synlogic Inc (Director · Aug 28, 2017 – Aug 28, 2017 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – Jul 24, 2017 · Past); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Mar 15, 2017 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Dec 30, 2016 · Past); Roka Bioscience Inc (Director · Sep 21, 2016 – Sep 21, 2016 · Past); Loxo Oncology Inc (Director · Aug 10, 2016 – Dec 8, 2017 · Past); Audentes Therapeutics Inc (Director · Jul 19, 2016 – Jul 19, 2016 · Past); Corvus Pharmaceuticals, Inc. (Director · May 18, 2016 – Jun 23, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 11, 2016 – May 11, 2016 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Mar 27, 2017 · Past); Otonomy Inc (Director · Nov 17, 2015 – Nov 25, 2015 · Past); Dimension Therapeutics (Director · Oct 27, 2015 – Oct 27, 2015 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Jul 21, 2015 · Past); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Jul 6, 2015 · Past); Glaukos Corporation (Director · Jun 24, 2015 – Aug 31, 2017 · Past); Intercept Pharmaceuticals Inc (Director · Apr 9, 2013 – Jul 17, 2015 · Past); Supernus Pharmaceuticals, Inc. (Director · May 4, 2012 – May 4, 2012 · Past); Anthera Pharmaceuticals Inc (Director · May 9, 2011 – Jan 30, 2013 · Past); Amarin Corporation plc (Director · Jan 1, 2011 – Sep 4, 2012 · Past); NxStage Medical Inc (Director · Jul 23, 2008 – Dec 9, 2010 · Past); Albireo Pharma Inc (Director · Feb 12, 2008 – Jun 9, 2009 · Past); Aryx Therapeutics Inc (Director · Nov 7, 2007 – Nov 13, 2007 · Past); Insulet Corporation (Director · May 14, 2007 – May 14, 2007 · Past); Volcano Corp (Director · Jun 14, 2006 – Jun 20, 2006 · Past); Given Imaging Ltd (Director · May 24, 2006 – May 24, 2006 · Past); Avanir Pharmaceuticals Inc (Director · Feb 13, 2006 – May 31, 2006 · Past) | Director · Jun 21, 2016 – Jun 27, 2016 · Past |
| Carl Gordon Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); ArriVent BioPharma, Inc. (Director · Jan 25, 2024 – Jan 30, 2024 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Adicet Bio, Inc. (Director · Sep 15, 2020 – Aug 21, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – Jun 16, 2021 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past) | Director · Jun 21, 2016 – Jun 27, 2016 · Past |
| Noubar Afeyan Other companies: Generate Biomedicines, Inc. (Chair of the Board · Since at least Feb 26, 2026); Foghorn Therapeutics Inc. (Director · Since at least Jan 13, 2026); Moderna, Inc. (Director · Since at least Dec 7, 2018); BG Medicine Inc (Director · Since at least Feb 3, 2011); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Mar 4, 2019 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 12, 2019 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 18, 2019 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – Mar 20, 2014 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Sep 25, 2013 · Past); Color Kinetics Inc (Director · Jan 3, 2006 – Aug 24, 2007 · Past); Agenus Inc. (Director · Jan 13, 2005 – Jun 7, 2007 · Past) | Director · Jun 21, 2016 – Jun 21, 2016 · Past |
| Carrie S. Cox Other companies: Solventum Corporation (Director · Since at least Apr 1, 2024); Organon & Co. (Executive Board Chair · Since at least Jun 2, 2021); Texas Instruments Incorporated (Director · Since at least Jul 28, 2015); electroCore, Inc. (Director · Jun 21, 2018 – Jun 7, 2019 · Past); Cardinal Health, Inc. (Director · Nov 4, 2015 – Nov 9, 2022 · Past); Celgene Corporation (Director · Jul 1, 2015 – Nov 20, 2019 · Past) | Director · Nov 20, 2019 – Jan 2, 2025 · Past |
| Elona Kogan Other companies: Apimeds Pharmaceuticals US, Inc. (Director · Since at least Mar 4, 2025); Seer, Inc. (CHIEF LEGAL OFFICER · Dec 3, 2020 – Feb 6, 2024 · Past); Ariad Pharmaceuticals Inc (Sr. V. P. - General Counsel · Jul 15, 2016 – Feb 16, 2017 · Past) | General Counsel · Mar 20, 2019 – Jan 2, 2020 · Past |
| Nishan M DeSilva Other companies: Ligand Pharmaceuticals Incorporated (VP, Finance & Strategy and CFO · Feb 9, 2012 – May 12, 2015 · Past); Talon Therapeutics Inc (Director · Apr 1, 2011 – Apr 1, 2011 · Past); Allos Therapeutics Inc (Director · Jun 22, 2010 – Dec 13, 2011 · Past) | Director · Since at least Jun 23, 2021 |
| Omid Farokhzad Other companies: Seer, Inc. (Chair and Chief Executive Officer · Since at least Dec 3, 2020); Senti Biosciences Holdings, Inc. (Director · May 25, 2021 – Jul 10, 2024 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Sep 19, 2013 · Past) | Director · Jun 21, 2016 – Jun 14, 2019 · Past |
| Timothy A. Springer Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Morphic Holding Inc (Director · Jun 26, 2019 – Aug 16, 2024 · Past); Scholar Rock Holding Corporation (Director · May 23, 2018 – Sep 3, 2019 · Past) | Director · Since at least Jun 21, 2016 |
| Bradford D Dahms Other companies: Jade Biosciences, Inc. (Chief Financial Officer · Since at least Jul 14, 2025); Theseus Pharmaceuticals Inc (President and CFO · Oct 6, 2021 – Feb 14, 2024 · Past) | Chief Financial Officer · Sep 3, 2019 – Jan 4, 2021 · Past |
| John Leaman Other companies: Traws Pharma, Inc. (Director · Since at least Oct 1, 2025); Impel Neuropharma Inc (Chief Fin. & Business Officer · Apr 22, 2021 – Jan 26, 2022 · Past) | CFO, Treas. & Hd Corp Strategy · Oct 26, 2017 – Jun 15, 2018 · Past |
All 37 people
| Person | Seat |
|---|---|
| Werner Cautreels Other companies: Traws Pharma, Inc. (Director · Since at least Apr 1, 2024); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 25, 2015 · Past) | President and CEO, Director · Jun 21, 2016 – Nov 13, 2017 · Past |
| Carsten Brunn Other companies: Surface Oncology Inc (Director · Jun 28, 2022 – Jun 28, 2022 · Past) | President, Chief Executive Officer, and Chairman, Board of Directors · Since at least Dec 1, 2018 |
| Göran Ando Other companies: EyePoint, Inc. (Non-Executive Chairman · Since at least Jun 25, 2018) | Director · Apr 24, 2020 – Jan 2, 2023 · Past |
| Kemal Malik Other companies: Acceleron Pharma Inc (Director · Jan 2, 2020 – Nov 19, 2021 · Past) | Director · Since at least Jul 1, 2024 |
| Kevin Tan Other companies: Solid Biosciences Inc. (CFO & Treasurer · Since at least Jan 9, 2023) | Chief Financial Officer · Sep 20, 2021 – Jan 3, 2022 · Past |
| Stephen Smolinski Other companies: Avalo Therapeutics, Inc. (Chief Commercial Officer · Jan 3, 2022 – Jan 4, 2022 · Past) | Chief Commercial Officer · Oct 26, 2017 – Jan 2, 2020 · Past |
| Timothy Barabe Other companies: Heartflow, Inc. (Director · Since at least Aug 7, 2025) | Director · Since at least May 9, 2022 |
| Adrian Bot | Director · Since at least Dec 16, 2025 |
| Ann K Donohue | VP Finance · May 7, 2019 – May 27, 2021 · Past |
| Aymeric Sallin | Director · Jun 21, 2016 – Jan 2, 2024 · Past |
| Blaine Davis | Chief Financial Officer · Since at least Nov 13, 2023 |
| Christopher M Jewell | Chief Scientific Officer · Nov 13, 2023 – Jan 10, 2025 · Past |
| David Abraham | GC, CCO & Corporate Secretary · Jun 21, 2016 – Jun 15, 2018 · Past |
| David Siewers | CFO and Treasurer · Jun 21, 2016 – Sep 20, 2017 · Past |
| Earl Sands | Chief Medical Officer · Jun 21, 2016 – Nov 17, 2017 · Past |
| Emily English | Chief Operations Officer · Since at least Apr 9, 2024 |
| June Ann Seymour | Chief Accounting Officer · Since at least Oct 27, 2025 |
| Leysan Shaydullina | Director · Jun 21, 2016 – Jun 21, 2016 · Past |
| Matthew Bartholomae | General Counsel, Secretary · Since at least Nov 5, 2026 |
| Metin Kurtoglu | Chief Technology Officer · Nov 13, 2023 – Jan 3, 2025 · Past |
| Michael Singer | Director · Since at least Nov 13, 2023 |
| Milos Miljkovic | Chief Medical Officer · Since at least Nov 13, 2023 |
| Nishan de Silva | Director · Since at least Nov 5, 2026 |
| Patrick Zenner | Director · Since at least Oct 30, 2025 |
| Peter Keller | Chief Business Officer · Jun 21, 2016 – Jul 7, 2017 · Past |
| Peter Traber | Head of Research and Development · Since at least May 26, 2026 |
| Takashi Kei Kishimoto | Chief Scientific Officer · Jun 21, 2016 – May 30, 2023 · Past |
Log in to ask 6ix AI your own questions about Cartesian Therapeutics, Inc.